Semaglutide Names in India: Brands, Doses, Status

This is a clinical-reference overview for a prescribing physician or hospital pharmacy stocking decision, not a patient dosing guide. It covers what's actually approved, why so many brand names exist for one molecule, the indication distinction that matters most, and the stocking implication for a hospital pharmacy.

Why are there suddenly dozens of semaglutide names in India?

Semaglutide's Indian patent expired on 20 March 2026, and multiple domestic manufacturers had generic versions ready to launch the same day, each under its own brand name for the identical active molecule. This is standard practice after patent expiry in India, not a sign of different drugs.

Within weeks, more than 40 manufacturers had entered or announced entry, and market trackers counted over a dozen DCGI-approved brand names in circulation by the following month. Natco Pharma launched under Semanat (multi-dose vial) and Semafull (pen device); Zydus Lifesciences under Semaglyn, Mashema and Alterme; Sun Pharma under Noveltreat; and Alkem under Semasize, Obesema and Hepaglide, according to reporting from BusinessToday tracking the launch wave.

What's the difference between Ozempic and Wegovy if the molecule is the same?

Ozempic is approved and marketed for type 2 diabetes management; Wegovy is the higher-dose formulation approved and marketed specifically for chronic weight management. Both are Novo Nordisk originator brands of semaglutide, and the dose progression and approved indication differ even though the underlying drug is identical.

Prescribing one brand for the other's indication is an off-label decision that carries a different risk and monitoring profile, and a hospital pharmacy substituting between them without a fresh prescription is substituting across indications, not just across brand names. Current CDSCO status and approved indication for each brand should be verified directly at cdsco.gov.in rather than assumed from a brand name alone.

Are the generic versions the same molecule as Ozempic and Wegovy?

Yes, in the sense that DCGI approval for a generic requires demonstrating bioequivalence to the originator molecule. The brand name and manufacturer differ; the semaglutide molecule and its mechanism of action, a GLP-1 receptor agonist, do not.

What can differ meaningfully between generic brands is delivery device, pen versus vial, dose increments available, and cold-chain handling requirements, all of which affect how reliably a hospital pharmacy can actually dispense a continuous course to a patient without a device or strength substitution mid-treatment.

What happened to pricing after generics entered?

Novo Nordisk cut Wegovy prices in India by up to 37% in November 2025, ahead of the patent expiry, and followed with a further cut of roughly 48% by April 2026 as generic competition intensified, bringing the Wegovy starter dose to approximately ₹5,660 per month according to BusinessToday's pricing coverage.

Generic entrants priced substantially below even the discounted originator: Natco's launch pricing ran approximately ₹1,290 to ₹1,750 per month depending on strength, roughly 90% below pre-generic originator pricing, per CNBC's coverage of the Indian launch. Every figure here is a manufacturer-stated launch or list price at the date reported and should be checked against current NPPA/DPCO status before quoting to a patient, since neither Ozempic nor Wegovy currently sits under a fixed DPCO price ceiling.

Is semaglutide under price control in India?

Semaglutide brands are not currently listed formulations under the NLEM price-control schedule, so pricing moves on manufacturer and market competition rather than a government ceiling. A figure quoted even a few weeks old should be reconfirmed via the National Pharmaceutical Pricing Authority before use.

That's precisely why semaglutide names and prices have both moved so fast since March 2026: no ceiling constrains either the originator's discounting or a new entrant's launch price, unlike a DPCO-scheduled formulation.

What should a hospital pharmacy actually stock?

A hospital pharmacy serving both an endocrinology and a bariatric or weight-management practice needs to stock against indication, not against whichever brand offers the best margin. Diabetes patients on originator Ozempic mid-course generally should not be switched to a differently branded generic without the prescribing physician's explicit sign-off, given device and dose-increment differences between brands.

Given the sheer number of new brand names entering monthly, a pharmacy that hasn't reconciled its formulary against current DCGI approvals risks stocking a brand that's already been withdrawn, renamed, or superseded by a newer strength from the same manufacturer.

Why does semaglutide stocking reliability matter for a hospital's own pharmacy?

Semaglutide is a chronic, ongoing injection therapy, not a one-time fill. A patient who can't refill the exact brand and strength their treatment started on inside the hospital walks it out to an outside chemist, and a hospital that can't guarantee continuity on a fast-changing SKU list loses that patient's entire ongoing refill relationship, not just one transaction.

That's a real operational problem specific to this drug class right now, given how quickly new generic brands are entering and how fast pricing is moving beneath them. Our managed hospital pharmacy services piece covers how a formulary is kept current against exactly this kind of fast-moving generic entry, and our prescription leakage piece covers what a single walked-out chronic-therapy prescription costs over its full treatment course.

Sources

1. 1Central Drugs Standard Control Organisation — drug approval status, Government of India
2. 2National Pharmaceutical Pricing Authority — drug pricing and DPCO status
3. 3Novo Nordisk gets US FDA approval for higher dose Wegovy, as India's generic semaglutide war begins — BusinessToday, March 2026
4. 4Novo further cuts semaglutide prices as generics enter India — BusinessToday, March 2026
5. 5India is launching cheap weight-loss drugs — but Novo Nordisk is betting its brands will stay on top — CNBC, March 2026
6. 6Generic versions of Novo's semaglutide launch today in India — Fierce Pharma, March 2026

This article is for informational purposes for clinicians and hospital administrators and is not a substitute for professional medical advice. Brand names, prices and approval status change quickly in this category; verify current status with CDSCO and NPPA before any prescribing or stocking decision.